If the guide wire moves in between implantation and surgery, it could result in the patient requiring additional surgery to correctly remove a safe margin of healthy tissue. This movement can also lead to the removal of more tissue than desired. In addition, due to the open incision created by the guide wire, surgery must be performed on the same day, creating workflow challenges for the hospital.
Many hospitals are now implementing radioactive seeds to replace the breast guide wire. This technique considerably reduces the incidence of additional surgery and removal of excess margin for the patient. The seeds also increase the time between lesion marking and surgery improving workflow, but they introduce new challenges regarding the ‘chain of custody’ for managing radioactive materials.
Endomag has developed a magnetic lesion marker (metallic pellet) for breast cancer called Magseed®. Magseed® works in conjunction with the Sentimag® to maintain the benefits of radioactive seeds, but avoiding their challenges. Sentimag® and Magseed® have FDA 510(k) clearance and are available in the United States.